Download Files:
Products Details
Product Description
– HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221)[1].
Web ID
– HY-155248
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C44H44N2O7
References
– [1]Lu Y, et al. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma. J Adv Res. 2023 Sep;51:181-196.. .
CAS Number
– 1448355-15-4
Molecular Weight
– 712.83
SMILES
– CN([C@@]1([H])CC2=CC=C(OC)C(OC3=CC=C(C[C@]4([H])N(C)CC5)C=C3)=C2)CCC6=C1C(OC7=C(OC)C=C5C4=C7)=C(OC(C8=CC=CC=C8)=O)C(OC)=C6
Clinical Information
– No Development Reported
Research Area
– cancer
Solubility
– 10 mM in DMSO
Target
– HDAC
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
